|Viable cell therapy treatment option presented by ASTM|
|Monday, 19 September 2011 08:54|
The clinical results were reported today by Amit N. Patel, MD, MS, associate professor of surgery at the University of Utah School of Medicine and national principal investigator for Aastrom's U.S. Phase 2 IMPACT-DCM clinical trial, in a poster presentation at the 15th Annual Heart Failure Society of America Scientific Meeting in Boston.
Twenty-one of the 25 (84%) ixmyelocel-T patients completed the 12-month visit. Seven of 15 (47%) of the control patients completed the 12-month visit, while an additional 5 of 15 (33%) of the control patients enrolled into the extension phase of the study and received ixmyelocel-T treatment. Results showed no difference in adverse events in treatment and control group patients after the initial post-operative period. ICM patients treated with ixmyelocel-T showed improved outcomes compared to control. Efficacy observations related to structural and functional end points including major adverse cardiovascular events (MACE), New York Heart Association (NYHA) functional classification, 6-minute walk distance, and septal wall thickening, were consistent with improved function of impaired myocardium.
“This study provides proof of principle that ixmyelocel-T can be delivered to the impaired myocardium despite the serious disease these patients have,” said Dr. Patel, adding, “Cellular therapy could represent a viable treatment option for DCM patients who currently have no good options available.”
Dr. Patel will present the poster, entitled: “Safety and Efficacy of Ixmyelocel-T, an Expanded Patient-Specific Mixed Cell Product, in Dilated Cardiomyopathy (IMPACT-DCM),” beginning at 5:45 P.M today. The poster will be on display from 9:30 A.M. to 7:00 P.M. (EST).
“The positive results from our 12-month analysis and evidence of positive trends in our six-month analysis of patients with DCM are encouraging and support our plans to complete clinical development and pursue regulatory review of ixmyelocel-T for the treatment of severe chronic cardiovascular conditions,” said Tim Mayleben, president and CEO of Aastrom. “Aastrom is currently conducting Phase 2 trials of ixmyelocel-T in patients with DCM and preparing to launch a pivotal Phase 3 clinical trial in the treatment of critical limb ischemia.”
In addition to the 12-month data from the IMPACT-DCM trial involving surgical administration of ixmyelocel-T, Aastrom also today announced positive results from a six-month interim analysis of DCM patients treated with ixmyelocel-T via catheter administration. In this analysis, functional improvements in efficacy parameters were consistent with those seen in the IMPACT-DCM trial results. In addition, the adverse event profile suggests that catheter administration of ixmyelocel-T is safe and appears to cause fewer adverse events compared to surgical administration of ixmyelocel-T.